Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MGLL | Q99685 | 10/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL229430 | 0.98 | MEN1 (0.70) | MEN1KMT2ACYP2D6MGLLLMNA | |
| SCHEMBL13391197 | 0.87 | MGLL (0.65) | MEN1KMT2AMGLLHSD11B1 | |
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL392801 | 0.86 | MGLL (0.68) | MEN1KMT2AMGLLLMNATP53 | |
| SCHEMBL11354827 | 0.85 | MEN1 (0.54) | MEN1KMT2ACYP2D6MGLLLMNA | |
| SCHEMBL8106011 | 0.85 | MGLL (0.58) | MEN1KMT2AMGLLLMNATP53 | |
| Tert-Butyl Formate SCHEMBL28875402 | 0.84 | MEN1 (0.54) | MEN1KMT2ACYP2D6MGLLLMNA | |
| Hydrochloric Acid SCHEMBL11355129 | 0.84 | MEN1 (0.56) | MEN1KMT2ACYP2D6MGLLLMNA | |
| SCHEMBL13944266 | 0.83 | MEN1 (0.69) | MEN1KMT2ACYP2D6TP53HSD11B1 | |
| SCHEMBL13390936 | 0.83 | MEN1 (0.54) | MEN1KMT2ACYP2D6MGLL | |
| SCHEMBL5218517 | 0.83 | MEN1 (0.69) | MEN1KMT2ACYP2D6MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-11160803-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2021-11-02 | — | — | US | disclosed |
| CN-106946796-B | Aminopyrimidine derivatives useful as modulators of kinase activity | 默克专利有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-10449192-B2 | Phthalazinone derivatives | KUDO PHARMACEUTICALS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| WO-2019072978-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | Basilea Pharmaceutica International AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-10080750-B2 | Aminopyrimidine derivatives for use as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-RE46942-E1 | 4-piperidinyl compounds for use as tankyrase inhibitors | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-5232924-A | Cardiovascular disorders | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-08-03 | — | — | US | disclosed |
| US-5206239-A | Cardiovascular disorders | SUNTORY LIMITED (JP) | 1993-04-27 | — | — | US | disclosed |
| EP-0441349-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4983606-A | Pharmaceutically-active phthalazine compounds | ZAMBON GROUP S.P.A. (IT) | 1991-01-08 | — | — | US | disclosed |
| EP-0401707-A1 | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| EP-0124476-B1 | CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1988-06-22 | — | — | EP | disclosed |
| US-4559349-A | TREATMENT OF PHYCHOSIS | CIBA GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0124476-A1 | Carboxamides, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1984-11-07 | — | — | EP | disclosed |
| US-4101662-A | DISUBSTITUTED PIPERIDINES | A. H. ROBINS COMPANY, INCORPORATED (US) | 1978-07-18 | — | — | US | disclosed |
| US-3968217-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10080750-B2 | Aminopyrimidine derivatives for use as modulators of kinase activity | CDK6, TK1, MAP3K19 | MEN1 3016/4885KMT2A 643/4885CYP2D6 2536/4885 |
| US-10449192-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | MEN1 1409/4885KMT2A 2203/4885CYP2D6 1407/4885 |
| US-11160803-B2 | Phthalazinone derivatives | NR0B1, NR0B2, NR2E1 | MEN1 1409/4885KMT2A 2203/4885CYP2D6 1407/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | MEN1 4478/4885KMT2A 2392/4885CYP2D6 3250/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | MEN1 1532/4885KMT2A 1279/4885CYP2D6 1852/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | MEN1 1419/4885KMT2A 2142/4885CYP2D6 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.